Transforming physician-led healthcare practices into scalable, transferable businesses — maximizing patient outcomes, developing staff for the next owner, and building the defensible enterprise value that attracts the right buyer at the right price.
On a $1M EBITDA practice, that delta is $3–4 million in additional enterprise value. The preparation costs $200–400K. The ROI is 10–20×. That is what the FRSS platform manufactures.
Most ophthalmology and optometry founders engage an advisor only months before they want to sell — with no preparation in place. A focused 6–12 month FRSS engagement closes that gap. Arrive at the table prepared. By the time an unprepared founder realizes the discount, the offer is already written.
Four phases. One outcome: the freedom to focus on what's next.
A structured 6–12 month operating engagement — not a consulting retainer. We get inside the P&L, fix what's broken, run operations to peak performance, scale for maximum valuation, and position you to sell to the right buyer.
Before you commit to a full engagement, we spend 30–45 days doing a deep diagnostic across all eight dimensions of transferability. You get a scored assessment, a dollar-quantified roadmap of addressable improvement, and a clear picture of exactly what a buyer will underwrite — and what they will discount.
I have spent twenty-five years building, running, and exiting healthcare businesses — ophthalmology and optometry are my core, and I also bring deep experience across dental, dermatology, orthopedics, spine, pain management, and multi-specialty platforms. Solo and multi-doctor groups, ASC-anchored operations, optical retail, MSOs and DSOs. Multiple leadership, growth, and exit roles across the career — on both the sell side and the buy side.
I served as the operating CEO responsible for EBITDA growth on a PE-backed multi-site healthcare platform — delivering 3× EBITDA growth over the engagement. Simultaneously, I was advising leading PE firms on how to evaluate businesses exactly like the ones you have built: their QoE findings, their investment thesis, their management team assessment.
That dual role is what makes this different. I know precisely what MSOs, DSOs, and PE-backed platforms are underwriting before they ever shake your hand. I know what buyers want from acquisitions and integrations — not just the financial synergies, but the operational readiness, the management bench, the clinical quality signal, and the staff stability that determines whether a deal creates or destroys value post-close.
Vaughan Advisors operates the FRSS platform — Fix, Run, Scale, Sell — as a productized operating engagement. Not a monthly advisory retainer. Not a slide deck. We get inside the practice, do the operational work, and season the results into the financials before a buyer ever sees them. And where integration advisory is needed — on either side of a transaction — we bring the same operator lens to making the combined business worth more than the sum of its parts.
Our commitment in every engagement: maximize patient outcomes, develop and prepare staff for the next owner, and build the kind of legacy value that endures past the closing table.
Every operational change passes through one filter: does this serve the patient better? A practice that serves patients better is also more defensible, more referable, and more valuable at exit. The two goals are not in tension.
The people who built this practice with you deserve continuity, development, and a real future under new ownership. We actively prepare your team — not just your financials — for the transition. A stable, capable staff is a valuation driver and a legacy asset buyers cannot ignore.
The EBITDA presented to buyers is the EBITDA actually produced through real operating improvement. We document every add-back honestly. We do not inflate numbers or obscure risk. Buyers underwrite the truth — we make sure the truth looks its best.
The right exit preserves what you built. The wrong exit erodes it. We spend 6–12 months ensuring you have the information, the preparation, and the leverage to get to the right buyer at the right terms — one who will honor your patients, your staff, and the mission you built.
Primary expertise in ophthalmology and optometry — with deep experience across dental, dermatology, orthopedics, spine, pain management, and other healthcare specialties. We know what MSOs and DSOs want from acquisitions and integrations, and we prepare founders to meet that bar.
Current market dynamics: PE pulled back through 2025 — eye-care PE-backed deal count fell from 35 in 2023 to 18 in 2024 and was softer still in 2025. Lending tightened, sponsors became more selective. But the same buyers who tightened criteria are now explicitly paying 1–2 extra multiple turns for transferable practices (published industry data). Strategic distributors have moved into the space at the top of the multiple range, particularly in retina. The market for prepared, founder-owned practices is the strongest it has been in five years. The window is open. Preparation takes 18–36 months. The question is where you are in that timeline.
Every engagement starts with a free Discovery Call. The Transferability Index Assessment is the entry product. From there, the engagement scales with the practice's needs and timeline.
The Discovery Call is free. Sixty minutes. No pitch deck, no retainer ask. We have a direct conversation about where your practice is, what a transferable exit would look like, and whether the FRSS platform is the right fit.